About us
Van Leeuwenhoeck Research (VLR) is an independent research company, enabling institutional investors and other professional investors to better understand the real value of innovative Life Sciences companies they invest in. VLR can tap into a selected circle of top analysts in L...
Published by: Marcel Wijma |
Date: 24 July 2010
Dutch/Danish biotech company Genmab saw a strong rebound in its share price of more than 50% from a low of DKK 40. The primary reason for this in our opinion was due to the outcome of a renegotiated partnership with GSK on Arzerra. This provides Genmab with a upfront payment of STG 90 million. The payment is inclusive of the reduced R&D expenses for Genmab on Arzerra, giving Genmab much needed financial stability and also the first sign towards earning back its investors trust. More to follow.
|
Published by: |
Date: 21 July 2010
There are rising problems with bacteria becoming resistant against antibiotics. MRSA is especially troublesome in hospitals, where patients with open wounds, invasive devices and weakened immune systems are at greater risk of infection than the general public. However, the is possibly a treatment for both preventing and treating diffi cult to treat infections like MRSA in a far more cheaper and effective way than vaccines or the current failing antibiotics. That answer might me a revived remedy: phage therapy.
|